



G-1

Catalog No: tcsc0027669	Catalo	og N	0:	tcsc	00)27	669
-------------------------	--------	------	----	------	----	------------	-----

Available Sizes
ze: 1mg
ze: 5mg
ze: 10mg
Specifications
AS No: 81639-98-1
ormula: 21 ^H 18 ^{BrNO} 3
athway: :hers
arget: trogen Receptor/ERR
urity / Grade: 98%
olubility: 20 :

Product Description

Observed Molecular Weight:

G-1 is a nonsteroidal, high-affinity and selective agonist of $\bf GPR30$ with a $\bf K_i$ of 11 nM.

IC50 & Target: Ki: 11 nM (GPR30)^[1]

In Vitro:

412.28





G-1 is a nonsteroidal, high-affinity and selective agonist of GPR30 with a K_i of 11 nM^[1]. Treatment with G-1 (10 μ M and 100 μ M) for 48 and 72 h significantly decreases cell proliferation (P50 value for G-1 is calculated to be 20 μ M. Treatment of A549 cells with G-1 at a concentration of 20 μ M reveals a significant increase in apoptosis, consistent with its antiproliferative effect (P[2]. Cell cycle analysis of H295R cells after 24 h of G-1 treatment demonstrates a cell cycle arrest in the G_2 phase. The presence of G-1 increases Bax expression while decreases Bcl-2^[3].

In Vivo: The results at 14 days post-injury show that the Basso mouse scale (BMS) scores are significantly higher in the G-1 group compared with the other groups $(P0.05)^{[1]}$. G-1 administration produces a statistically significant decrease in tumor volume from day 14 post treatment. Grafted tumors harvested after three-week treatment with G-1 show a significant decrease in tumor weight compare to vehicle treated animals^[3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!